Rajasree Chakraborty

Rajasree Chakraborty

Auto-generated profile, based on publicly available information

Rajasree Chakraborty

Center for AIDS Health Disparities Research; Department of Microbiology, Immunology, and Physiology, Meharry Medical College, Nashville, TN

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Circulation Research
Verified
Journal Article
Closed access
PPPrem Prakash
Prem Prakash
BVBerwin Singh Swami Vetha
Berwin Singh Swami Vetha
RCRajasree Chakraborty
Rajasree Chakraborty
TWTara-Yesomi Wenegieme
Tara-Yesomi Wenegieme
Sepiso Kenias MasengaSepiso Kenias Masenga
Sepiso Kenias Masenga
CDChandravanu Dash
Chandravanu Dash
HIV type 1 (HIV-1) is the causative agent of AIDS. Since the start of the epidemic, HIV/AIDS has been responsible for ≈40 million deaths. Additionally, an estimated 39 million people are currently infected with the virus. HIV-1 primarily infects immune cells, such as CD 4+ (cluster of differentiation 4 + ) T lymphocytes (T cells), and as a consequence, the number of CD 4+ T cells progressively declines in people living with HIV. Within a span of ≈10 years, HIV-1 infection leads to the systemic failure of the immune system and progression to AIDS. Fortunately, potent antiviral therapy effectively controls HIV-1 infection and prevents AIDS-related deaths. The efficacy of the current antiviral therapy regimens has transformed the outcome of HIV/AIDS from a death sentence to a chronic disease with a prolonged lifespan of people living with HIV. However, antiviral therapy is not curative, is challenged by virus resistance, can be toxic, and, most importantly, requires lifelong adherence. Furthermore, the improved lifespan has resulted in an increased incidence of non-AIDS–related morbidities in people living with HIV including cardiovascular diseases, renal disease, liver disease, bone disease, cancer, and neurological conditions. In this review, we summarize the current state of knowledge of the cardiovascular comorbidities associated with HIV-1 infection, with a particular focus on hypertension. We also discuss the potential mechanisms known to drive HIV-1–associated hypertension and the knowledge gaps in our understanding of this comorbid condition. Finally, we suggest several directions of future research to better understand the factors, pathways, and mechanisms underlying HIV-1–associated hypertension in the post-antiviral therapy era.

16 May 2022 in Nanomedicine
Verified
Journal Article
Closed access
CSChaitali Surve
Chaitali Surve
ABAnanya Banerjee
Ananya Banerjee
ASAnupriya S
Anupriya S
RCRajasree Chakraborty
Rajasree Chakraborty
DKDhiraj Kumar
Dhiraj Kumar
SPSRINIVAS OF PATNAIK
SRINIVAS OF PATNAIK
Aim: To evaluate the efficacy of novel methotrexate-loaded nanoparticles (MTX-NPs) in vitro and in vivo in the treatment of breast cancer. Materials & methods: MTX-NPs were tested for cellular upta...

3 July 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NSNicklas Sapp
Nicklas Sapp
PPPrem Prakash
Prem Prakash
RCRajasree Chakraborty
Rajasree Chakraborty
MBMuthukumar Balasubramaniam
Muthukumar Balasubramaniam
CDChandravanu Dash
Chandravanu Dash
Retroviral replication has two distinctive features- reverse transcription of the viral single stranded RNA genome into a double stranded DNA copy and integration of the viral DNA into the host genome. Viral DNA integration establishes a provirus in the host genome that resides as a stable viral genetic element for the life of the cell and serves as the source of progeny virion production. However, integration requires the viral preintegration complex (PIC) to overcome the structural barriers of the densely packed chromatin to access the host DNA. Eukaryotic chromosomes are organized by the repeating units of nucleosomes. A nucleosome comprises of a DNA segment of ∼150 base pairs compacted by an octamer of histone proteins, which regulate access to the DNA through a network of chemical modifications. Interestingly, several histone tail modifications play an outsized role in regulating retroviral integration into specific regions of the host genome. Studies in the last few decades have identified several viral and host factors that promote retroviral integration and regulate integration targeting. However, the interaction between the PIC and host nucleosomes that promote retroviral integration is an understudied area. In this review, we will focus on the biochemical and molecular interactions of retroviral PICs with the host nucleosome in an attempt to identify the barriers and factors involved in retroviral integration.